NextCure Inc (NASDAQ:NXTC) has received an average broker rating score of 1.17 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company.
Brokers have set a 1-year consensus price objective of $25.33 for the company and are expecting that the company will post ($0.47) EPS for the current quarter, according to Zacks. Zacks has also assigned NextCure an industry rank of 53 out of 256 based on the ratings given to related companies.
A number of equities research analysts have issued reports on NXTC shares. Bank of America reissued a “buy” rating and set a $43.00 target price (up previously from $36.00) on shares of The Medicines in a research note on Tuesday, July 9th. Piper Jaffray Companies lowered shares of Cypress Semiconductor from an “overweight” rating to a “neutral” rating in a research note on Monday, June 3rd. Finally, Morgan Stanley lowered shares of Meili from an “equal weight” rating to an “underweight” rating and decreased their target price for the company from $14.00 to $4.20 in a research note on Monday, June 3rd.
NextCure (NASDAQ:NXTC) last issued its earnings results on Monday, June 10th. The company reported ($4.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($3.93). The business had revenue of $1.36 million for the quarter. Equities research analysts expect that NextCure will post -2.08 earnings per share for the current fiscal year.
In other NextCure news, Director Stella Xu purchased 125,000 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $1,875,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder X L.P. Canaan purchased 50,000 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $750,000.00. The disclosure for this purchase can be found here.
NextCure Company Profile
There is no company description available for NextCure Inc
Featured Story: How are Outstanding Shares Different from Authorized Shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.